GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up “three or four times a week” to hound him with the same question. At such a critical moment in US ...

With approximately 60% of prescription drugs coming from Europe, including major brands like Ozempic, Botox and Eliquis, many ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...

Weight loss medications such as Wegovy and Zepbound have garnered an enormous amount of attention recently for their ability to help some users lose significant amounts of weight relatively easily.

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.